SCHEMBL4548663

SCHEMBL4548663

O=C(Nc1ccc(F)cc1)c1cccc2cc(Oc3ccnc4[nH]ccc34)ccc12

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.69
MET P08581 8/20 0.66
LCK P06239 2/20 0.57
AURKA O14965 1/20 0.57
CSF1R P07333 1/20 0.57
BRAF P15056 1/20 0.57
FLT1 P17948 1/20 0.57
FGFR2 P21802 1/20 0.57
FLT4 P35916 1/20 0.57
TEK Q02763 1/20 0.57
AURKB Q96GD4 1/20 0.57
KIT P10721 2/20 0.57
FLT3 P36888 2/20 0.57
EGFR P00533 1/20 0.57
PDGFRB P09619 1/20 0.57
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
RIPK1 Q13546 1/20 0.55
RIPK3 Q9Y572 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747428 0.92 KDR (0.68) KDRMETLCKAURKACSF1R
SCHEMBL2748584 0.91 KDR (0.70) KDRMETLCKAURKACSF1R
SCHEMBL4548665 0.91 KDR (0.61) KDRMETLCKAURKACSF1R
SCHEMBL4548664 0.91 KDR (0.74) KDRMETLCKAURKACSF1R
SCHEMBL4548667 0.90 KDR (0.59) KDRMETLCKAURKACSF1R
SCHEMBL4548666 0.90 KDR (0.71) KDRMETLCKAURKACSF1R
SCHEMBL4548672 0.86 KDR (0.68) KDRMETLCKAURKACSF1R
SCHEMBL4548668 0.86 KDR (0.71) KDRMETBRAFFLT1FLT4
SCHEMBL2749268 0.83 MET (0.55) KDRMETBRAFKITFLT3
SCHEMBL2747627 0.83 KDR (0.52) KDRMETLCKAURKABRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885MET 3/4885LCK 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.